Print
Email
Print Edition Stories
Friday, February 11, 2011
PerkinElmer's Friel pulls in $3M in restricted stock
By Tim McLaughlin - Boston Business Journal
Raytheon unveils updated exoskeleton robotics suit
Regenerative medicine firms make business of creating skin
MHT's Emerging Technologies Forum: Health IT and the Cloud
PerkinElmer Inc. (NYSE: PKI) CEO Robert Friel this week received restricted stock worth nearly $3 million and the option to buy about 200,000 shares.
The CEO of the Waltham, Mass.-based company disclosed the awards in a filing with the Securities and Exchange Commission. He received 108,031 shares of restricted stock that’s currently worth $2.9 million. The stock will vest over the next three years.
Friel also received the option to buy 198,337 PerkinElmer shares. The exercise price on the stock is $26.58. The options expire in seven years, according to the SEC filing.
PerkinElmer shares on Thursday were up 22 cents at $26.91 in afternoon trading. The stock is up 30 percent over the past year, outperforming the 23 percent gain on the S&P 500.
PerkinElmer’s products are used by research laboratories and the life sciences industry. For example, the company recently announced that its family cord blood banking business, ViaCord, released a stem cell unit intended to treat cerebral palsy.
PerkinElmer recently completed the divestiture of its illumination and detection business in a deal with private-equity buyers. The transaction, which involved its plant in Salem, Mass., resulted in a pre-tax gain of $315 million in the fourth quarter.
Meanwhile, revenue from continuing operations in the fourth quarter was $470 million, up 10 percent from the year-ago period.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
